avadomide (CC-122) / BMS  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
avadomide (CC-122) / BMS
NCT02417285: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Checkmark For r/rNHL (DLBCL, FL and MZL) at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: For r/rNHL (DLBCL, FL and MZL) at ASH 2017 [screenshot]
Checkmark In R/R DLBCL or iNHL at ASH 2016
Dec 2016 - Dec 2016: In R/R DLBCL or iNHL at ASH 2016
Completed
1b
75
Europe
Obinutuzumab, GA-101, CC-122
Celgene
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
05/19
09/23
NCT02509039: A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Completed
1
15
Japan
CC-122
Celgene
Lymphoma, Non-Hodgkin
05/23
05/23
NCT01421524: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Completed
1
271
Europe, US
CC-122
Celgene
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
11/23
11/23
NCT02031419: Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Terminated
1
174
Europe, Canada, US
CC-122, CC-223, Rituximab, CC-292
Celgene
Lymphoma, Large B-Cell, Diffuse
12/23
12/23
NCT05688475: A Rollover Study of CC-122

Active, not recruiting
1
12
Europe, Japan, US
CC-122, Avadomide, BMS-986381, Dexamethasone
Bristol-Myers Squibb
Non-Hodgkin Lymphoma
02/26
02/26

Download Options